Test Price
2,800 AED✅ Home Collection Available
ALS2 Gene Primary Lateral Sclerosis, Juvenile Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This test identifies pathogenic variants in the ALS2 gene, the definitive cause of juvenile primary lateral sclerosis (JPLS) and infantile-onset ascending hereditary spastic paralysis (IAHSP). With a 99.9% diagnostic sensitivity achieved through targeted next-generation sequencing (NGS) performed at our ISO-certified facility, the report provides clinicians with actionable, DHA-compliant genetic evidence to guide prognosis, family planning, and early therapeutic intervention.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Courier (8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance with a DHA-licensed genetic counselor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Inclusions
- Full ALS2 gene sequencing (all exons ±20 bp)
- Copy number variation (CNV) analysis
- Bioinformatic reanalysis for variants of uncertain significance (VUS)
- Pre- and post-test genetic counseling session
- Family pedigree chart construction
Corporate Lab: DNA Labs UAE
DHA Facility License: 1143
Test Overview & Methodology
This NGS-based test comprehensively analyzes the ALS2 gene for mutations causing juvenile primary lateral sclerosis and related motor neuron disorders. It delivers a definitive molecular diagnosis in as little as 3 weeks, leveraging a targeted, high-coverage sequencing approach that minimizes incidental findings compared to whole-exome tests.
| Feature | Our Test (ALS2-NGS) | Closest Alternative (HSP Gene Panel) |
|---|---|---|
| Methodology | Targeted NGS with 500x mean depth | Multi-gene panel (30-60 genes), often lower depth |
| Turnaround Time | 3-4 weeks | 6-8 weeks (typical) |
| Coverage of ALS2 | 100% of coding region + exon-intron boundaries | ≥98% (may miss deep intronic variants) |
| Interpretation | Gene-specific ACMG classification with pediatric neurology input | Generalized variant calling, may require follow-up |
| Genetic Counseling | Included: pre-test pedigree & post-test phone consultation | Often optional or outsourced |
Physician Insight & Safety Protocols
"Juvenile primary lateral sclerosis arises from biallelic ALS2 mutations, and this targeted NGS test provides families with the genetic certainty required to navigate a challenging neurodegenerative diagnosis. The molecular findings must be interpreted alongside clinical examination, neuroimaging, and electrophysiological studies by a pediatric neurologist. I emphasize that treatment decisions should never be based solely on genetic results without comprehensive clinical correlation."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA ID: 9294403
⚠️ Medication Advisory
Do not stop or adjust any prescribed medications (including baclofen, tizanidine, or other spasticity therapies) based solely on genetic test findings. Always consult your treating physician before making any changes to your treatment regimen. Genetic results provide diagnostic clarity but do not replace ongoing clinical management.
🔴 Safety & Exclusion Criteria
- Exclusion Criteria: Inability to provide a blood sample or FTA card; patients with severe coagulopathy (INR > 2.0) require physician clearance; neonates under 3 kg unless medically justified.
- ER Red Flags: If the patient or family member experiences acute psychological distress, suicidal ideation, or severe anxiety following result disclosure, seek immediate psychiatric emergency services or call 998 (UAE Ambulance).
- Genetic test results must be disclosed during a formal genetic counseling session; self-interpretation is strongly discouraged.
Patient FAQ & Clinical Guidance
1. How accurate is the ALS2 gene NGS test for diagnosing juvenile primary lateral sclerosis?
This targeted NGS test achieves 99.9% diagnostic sensitivity for detecting pathogenic ALS2 variants when performed on a blood sample in a DHA-licensed laboratory. The assay covers all coding exons and flanking intronic regions with 500x mean depth, ensuring reliable detection of single-nucleotide variants, small indels, and copy number changes.
2. What sample types are accepted, and is a home collection available in Dubai?
We accept whole blood (3-5 mL in EDTA), extracted DNA, or a single drop of blood on an FTA card. VIP mobile phlebotomy and temperature-controlled cold-chain home collection are available across the UAE daily from 8 AM to 11 PM. For patients outside Dubai, secure medical courier retrieval can be arranged.
3. Will my health insurance cover the cost of the ALS2 genetic test in the UAE?
Direct billing verification is conducted through WhatsApp at +971 54 548 8731. Many UAE insurers cover this test when pre-authorized by a pediatric neurologist or clinical geneticist. Our billing team can assist with documentation and prior authorization requests for your specific plan.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Compliance
All genetic testing and data handling at DNA Labs UAE comply strictly with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governs the collection, processing, and storage of personal and genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulates electronic health records and telemedicine practices.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishes the framework for clinical testing safety and informed patient consent.
Your genetic information is encrypted, access-controlled, and never shared with third parties without your explicit written consent. DNA Labs UAE is fully licensed by the Dubai Health Authority (DHA License No. 1143).
Clinical & Logistical Metadata
| Test Name | ALS2 Gene Primary Lateral Sclerosis, Juvenile Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 21–28 Days (3–4 Weeks) |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with 500x Mean Depth |
| ICD-10-CM Code | G12.21 |
| LOINC Code | 90202-2 |
| DHA Facility License & Address | DHA License #1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians